Profound Medical Announces Upcoming June 2023 Investor Events
30 May 2023
Radiation TherapyDrug Approval
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announces the following investor events in June:
PRO-Talk Episode 5, “Unlocking the Potential of TULSA-PRO®”: Profound will be hosting a live webinar on Tuesday, June 6, 2023 at 6:00 p.m. ET, during which the following esteemed TUSLA-PRO® users will share their firsthand experiences with the technology: Y. Mark Hong, M.D. (Integrative Urology, Phoenix, AZ); Stephen Scionti, M.D. (Scionti Prostate Center / HALO Precision Diagnostics); Daniel Costa, M.D. (UT Southwestern); and Xiaosong Meng, M.D., Ph.D. (UT Southwestern). In addition, Profound management will provide a corporate overview, highlighting significant milestones, and unveiling interim 5-year follow-up data from the TACT (TULSA-PRO® Ablation Clinical Trial) pivotal study. To register for the PRO-Talk webinar, please use this link.
2023 Jefferies Healthcare Conference: Profound management is scheduled to present on Wednesday, June 7, 2023 at 4:30 p.m. ET in New York City. The presentation will be broadcast live and archived on the Company's website at under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.